Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-19-015171
Filing Date
2019-08-09
Accepted
2019-08-09 17:02:04
Documents
43
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0619_actiniumpharma.htm 10-Q 461249
2 CERTIFICATION f10q0619ex31-1_actinium.htm EX-31.1 8558
3 CERTIFICATION f10q0619ex31-2_actinium.htm EX-31.2 8521
4 CERTIFICATION f10q0619ex32-1_actinium.htm EX-32.1 4262
5 CERTIFICATION f10q0619ex32-2_actinium.htm EX-32.2 4000
  Complete submission text file 0001213900-19-015171.txt   2254368

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE atnm-20190630.xml EX-101.INS 261561
7 XBRL SCHEMA FILE atnm-20190630.xsd EX-101.SCH 37815
8 XBRL CALCULATION FILE atnm-20190630_cal.xml EX-101.CAL 32492
9 XBRL DEFINITION FILE atnm-20190630_def.xml EX-101.DEF 114084
10 XBRL LABEL FILE atnm-20190630_lab.xml EX-101.LAB 274860
11 XBRL PRESENTATION FILE atnm-20190630_pre.xml EX-101.PRE 188799
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 191013661
SIC: 2834 Pharmaceutical Preparations